Status:
TERMINATED
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Nasopharyngeal Neoplasms
Eligibility:
All Genders
18-99 years
Brief Summary
In an effort to identify genetic factors linked to the development of nasopharyngeal cancer (NPC), the researchers identified and sampled 2,394 individuals from Taiwanese families in which two or more...
Detailed Description
The purpose of this proposed study is to evaluate the clinical utility of serum EBV antibody testing for the identification of individuals at increased risk of nasopharyngeal carcinoma (NPC) within hi...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- The 2,394 unaffected family members who previously participated in the family study of nasopharyngeal carcinoma (NPC) in Taiwan between 1996 and 2004.
Exclusion
Key Trial Info
Start Date :
July 5 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 2 2020
Estimated Enrollment :
952 Patients enrolled
Trial Details
Trial ID
NCT00393224
Start Date
July 5 2005
End Date
June 2 2020
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University
Taiwan, China